Financing channel feed – Endpoints News

Financing channel feed

Following positive data for pulmonary fibrosis drug, Pliant to sell $175M in stock

3 years ago

VC investor Paul Manning donates $100M to UVA for new R&D institute

3 years ago

Alvotech raises $137M months after FDA rejected Humira biosimilar

3 years ago

Sesen takes next step after investor attack, calls for shareholder vote to approve merger

3 years ago

After hypertension competitor gets bought, Mineralys lines up IPO plans

3 years ago

After hashing out comeback plans, Deciphera looks to raise $125M from stock sale

3 years ago

Pathalys inks development deal with Abingworth company, raising $150M

3 years ago

Bluebird hopes to raise upwards of $100M by selling shares

3 years ago

The conference is back. What about the industry? Taking the biotech pulse at #JPM23

3 years ago

With CEO search, PhIII study underway, Fulcrum Therapeutics raises $125M from stock offering

3 years ago

Ready to expand, GenScript raises $224M for CDMO focused on antibodies, cell and gene therapies

3 years ago

Leap Therapeutics jumps into growing Claudin18.2 field by buying Flame Biosciences

3 years ago

LinusBio secures Series A for diagnostic platform that uses a single strand of hair

3 years ago

Scoop: Biotech developing oral Alzheimer's drug is on $50M hunt

3 years ago

Q&A: How to attract the eye of an early investor in biotech R&D tools

3 years ago

Sanofi extends commitment to $750M biotech startup fund

3 years ago

Data to dollars: Geron sells stock to raise over $200M after PhIII readout on MDS drug

3 years ago

Updated: Agilent throws down $725M to double manufacturing capacity for nucleic acids to meet API demand

3 years ago

Scoop: Rakuten billionaire lines up $70M for photoimmunotherapy

3 years ago

Updated: New Apple Tree biotech emerges with antibodies that might pair with Amgen, Mirati's KRAS drugs

3 years ago

Amolyt hauls in €130M round to fund PhIII trial of hypoparathyroidism drug

3 years ago

Tumor gene therapy developer rebrands, emerges with $30M from blue-chip investors

3 years ago

Synthekine nabs $100M to boost IL-2 programs after rivals hit setbacks

3 years ago

Updated: Stealth biotech Perceive raises $78M from J&J and Deerfield, says little about eye disease programs

3 years ago

First page Previous page 39 40 414243 44 45 Next page Last page